



31 July 2012

Resonance Health Ltd (ASX:RHT) Appendix 4C – 4th Quarter Cash Flow Report

Resonance Health Limited today released its fourth quarter Cash Flow Report for the period ending 31 July 2012.

Cash at 30 June 2012 was \$1,180,171 representing a decrease of \$42,000 for the June quarter. This compares to a net cash outflow of \$77,000 in the previous quarter. The Company continues to have no debt.

Receipts from customers were down 43% on the prior quarter primarily due to significantly increased debtors and unearned income. FerriScan sales revenue was down 11% on the prior quarter.

Research and development expenditure during the full 12 months has been focused on the development of software technology to accurately quantify liver fat and liver fibrosis. The project focused on the assessment of liver fat has been successfully completed and an application has been submitted to the FDA for marketing clearance of HepaFat™ Scan. The liver fibrosis project is also nearing completion. Expenditure on research and development is therefore expected to be lower in the 2012/13 financial year.

An amount of \$165,314 was received in the quarter for the Research and Development Tax Concession FY 2010-2011.

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Naomi Haydari
Company Secretary
T: +61 8 9286 5300
E: naomih@resonancehelath.com

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

30 June 2012

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date \$A'000
1.1 Receipts from customers	288	1,452
1.2 Payments for (a) staff costs	(383)	(1,362)
(b) advertising and marketing	(75)	(210)
(c) research and development	(96)	(493)
(d) leased assets	-	-
(e) other working capital	(40)	(354)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	23	124
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/received	165	577
1.7 Other Receipts/Payments (a) consulting & professional services	15	(27)
(b) statutory & compliance	(17)	(149)
(c) grants	78	128
Net operating cash flows	(42)	(314)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitment

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)	(41)	(314)
	Cash flows related to investing activities		
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	(9)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	Net investing cash flows	(0)	(9)
1.14	Total operating and investing cash flows	(42)	(323)
	Cash flows related to financing activities		
1.15	Proceeds from issues of shares, options, etc.	-	-
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (costs of capital raising)	-	-
	Net financing cash flows	-	-
	Net increase (decrease) in cash held	(42)	(323)
1.21	Cash at beginning of quarter/year to date	1,222	1,503
1.22	Exchange rate adjustments to item 1.20		
1.23	Cash at end of quarter	1,180	1,180

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	25
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

\$25K – Directors fees

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A.

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	180	222
4.2 Deposits at call	-	-
4.3 Bank overdraft		
4.4 Other (provide details)		
- Term deposits	1,000	1,000
Total: cash at end of quarter (item 1.22)	1,180	1,222

Acquisitions and disposals of business entities

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Naomi Haydari
Company Secretary

+ See chapter 19 for defined terms.